Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thorsten Fuereder

Showing results (41-50 of 73) with videos related to

Pageof 8
Sort By:
Cancer Medicine|November 27, 2025
Monotherapy With Immune Checkpoint Inhibitors in Patients With Recurrent and/or Metastatic Sinonasal Squamous Cell CarcinomaAlexander Lein, Thorsten Fuereder, Manuel Stoeth, et al.
European Journal of Clinical Investigation|June 4, 2021
Impact of COVID-19 lockdown on routine oncology versus emergency care at a high volume cancer centreChristoph Minichsdorfer, Georg Jeryczynski, Christoph Krall, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 30, 2011
Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptakeThorsten Fuereder, Thomas Wanek, Pamina Pflegerl, et al.
Clinical & Experimental Metastasis|December 8, 2023
Clinical characteristics, treatment, and outcome of patients with large cell neuroendocrine carcinoma of the lung and brain metastases - data from a tertiary care centerPetar Popov, Ariane Steindl, Ladislaia Wolff, et al.
BMC Infectious Diseases|May 28, 2026
Real-world evidence from a tertiary academic center: clinical characteristics, microbiology and outcomes of oncology patients with febrile neutropenia presenting to the emergency departmentMarkus Kleinberger, Petar Popov, Anna Pfarrhofer, et al.
Anticancer Research|February 28, 2023
Real-world Data of Palliative First-line Checkpoint Inhibitor Therapy for Head and Neck CancerSandro M Wagner, Teresa Magnes, Thomas Melchardt, et al.
Clinical Nuclear Medicine|April 26, 2019
Comparison of RECIST, iRECIST, and PERCIST for the Evaluation of Response to PD-1/PD-L1 Blockade Therapy in Patients With Non-Small Cell Lung CancerLucian Beer, Maximilian Hochmair, Alexander R Haug, et al.
Cancer|July 20, 2023
Risk as a pattern over time: Delineation of time-dependent risk factors in biological, psychological, and social variables in cancer patientsMatthias Knefel, Elisabeth L Zeilinger, Simone Lubowitzki, et al.
Breast (Edinburgh, Scotland)|May 7, 2026
HER2-directed therapy is associated with an increased rate of cardiologic emergency department visits in real-world breast cancer patientsSandra Mayer, Anna Pfarrhofer, Sophie M Neubauer, et al.
Journal for Immunotherapy of Cancer|March 26, 2022
DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinomaAngelika Martina Starzer, Gerwin Heller, Erwin Tomasich, et al.
Pageof 8

Showing results (41-50 of 73) with videos related to

Sort By:
Pageof 8
Cancer Medicine|November 27, 2025
Monotherapy With Immune Checkpoint Inhibitors in Patients With Recurrent and/or Metastatic Sinonasal Squamous Cell CarcinomaAlexander Lein, Thorsten Fuereder, Manuel Stoeth, et al.
European Journal of Clinical Investigation|June 4, 2021
Impact of COVID-19 lockdown on routine oncology versus emergency care at a high volume cancer centreChristoph Minichsdorfer, Georg Jeryczynski, Christoph Krall, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 30, 2011
Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptakeThorsten Fuereder, Thomas Wanek, Pamina Pflegerl, et al.
Clinical & Experimental Metastasis|December 8, 2023
Clinical characteristics, treatment, and outcome of patients with large cell neuroendocrine carcinoma of the lung and brain metastases - data from a tertiary care centerPetar Popov, Ariane Steindl, Ladislaia Wolff, et al.
BMC Infectious Diseases|May 28, 2026
Real-world evidence from a tertiary academic center: clinical characteristics, microbiology and outcomes of oncology patients with febrile neutropenia presenting to the emergency departmentMarkus Kleinberger, Petar Popov, Anna Pfarrhofer, et al.
Anticancer Research|February 28, 2023
Real-world Data of Palliative First-line Checkpoint Inhibitor Therapy for Head and Neck CancerSandro M Wagner, Teresa Magnes, Thomas Melchardt, et al.
Clinical Nuclear Medicine|April 26, 2019
Comparison of RECIST, iRECIST, and PERCIST for the Evaluation of Response to PD-1/PD-L1 Blockade Therapy in Patients With Non-Small Cell Lung CancerLucian Beer, Maximilian Hochmair, Alexander R Haug, et al.
Cancer|July 20, 2023
Risk as a pattern over time: Delineation of time-dependent risk factors in biological, psychological, and social variables in cancer patientsMatthias Knefel, Elisabeth L Zeilinger, Simone Lubowitzki, et al.
Breast (Edinburgh, Scotland)|May 7, 2026
HER2-directed therapy is associated with an increased rate of cardiologic emergency department visits in real-world breast cancer patientsSandra Mayer, Anna Pfarrhofer, Sophie M Neubauer, et al.
Journal for Immunotherapy of Cancer|March 26, 2022
DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinomaAngelika Martina Starzer, Gerwin Heller, Erwin Tomasich, et al.
Pageof 8